<code id='FF634B0424'></code><style id='FF634B0424'></style>
      • <acronym id='FF634B0424'></acronym>
      <center id='FF634B0424'><center id='FF634B0424'><tfoot id='FF634B0424'></tfoot></center><abbr id='FF634B0424'><dir id='FF634B0424'><tfoot id='FF634B0424'></tfoot><noframes id='FF634B0424'>
      • <optgroup id='FF634B0424'><strike id='FF634B0424'><sup id='FF634B0424'></sup></strike><code id='FF634B0424'></code></optgroup>
        5. <b id='FF634B0424'><label id='FF634B0424'><select id='FF634B0424'><dt id='FF634B0424'><span id='FF634B0424'></span></dt></select></label></b><u id='FF634B0424'></u>
          <i id='FF634B0424'><strike id='FF634B0424'><tt id='FF634B0424'><pre id='FF634B0424'></pre></tt></strike></i>
           
   
   
   
 

  
           
   
           
    
           
     
          
       Home / hotspot / explore      
           
     
           
      
          explore 
           
      
           
      
           
       2025-09-30 17:08:22 
   
      
           
      
           
                        
          explore  
          
                                   
                 
                                      author：Wikipedia   
                                        
                                      
                                      Page View：7729
                                  
                                    
          
                                   
          Trump Campaign Event In Nevada
          Ethan Miller/Getty Images
          WASHINGTON — Former President Trump is back to campaigning for tying Medicare drug prices to lower prices abroad.
          In Trump fashion, he claimed in a video announcement this month that he is the “only president in modern times” to take on the drug industry — and dinged President Biden directly.
          advertisement
          “Biden canceled my tough-on-pharma policies the moment he had a chance,” Trump said.
          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!					
          GET STARTED													Log In											
                      
                              
          
                                 Previous article：

                                
                                          Acelyrin, a rare IPO success, stumbles in its first big test
                                
                            
          Next article：  
                                      
                                          Psychedelics group wrestles with new pharma identity
                                                                    
          

      
           
    


       
       
       
    
     
           
    
           
    
           
   
      
     
           
      
           
       
          Related articles